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Role of endothelin and nitric oxide imbalance in the pathogenesis of
hypoxia-induced arterial hypertension.
Background. We have recently demonstrated that prolonged hypobaric
hypoxia can lead to a hematocrit-independent sustained arterial hyperten-
sion (HTN) in genetically normotensive Sprague-Dawley rats. The rise in
blood pressure in the hypoxic animals was accompanied by a marked but
transient increase in plasma endothelin level. In addition, hypoxia has
been shown to decrease nitric oxide (NO) production by cultured endo-
thelial cells. This study was designed to test the hypothesis that hypoxia-
induced HTN may be mediated by increased endothelin and/or decreased
NO production.
Methods. Blood pressure, plasma endothelin and urinary NO metabo-
lites (NOx) were monitored in rats during a 24-day exposure to hypobaric
hypoxia (air pressure 5 390 mm Hg). The results were compared with
those obtained in animals maintained under normoxic condition (control
group). To test the possible role of excess endothelin and depressed NO
production, the studies were repeated using subgroups of animals treated
with either an endothelin receptor ET-A/B blocker (L-754,142) or L-
arginine.
Results. The untreated hypoxic group exhibited a threefold rise in
plasma endothelin and a threefold fall in urinary NOx, prior to the onset
of HTN. Endothelin receptor blockade led to a further fall in urinary NOx
excretion and failed to mitigate HTN. In contrast, L-arginine supplemen-
tation improved the urinary NOx excretion and prevented HTN. Neither
therapy affected the hypoxia-induced erythrocytosis.
Conclusions. We conclude that hypoxia-induced HTN is associated with
depressed NO production and can be mitigated by L-arginine supplemen-
tation.
In an earlier study, we described a new model of
sustained systemic hypertension (HTN) induced by pro-
longed hypobaric hypoxia in genetically normotensive
Sprague-Dawley rats [1]. The observed HTN was not
related to the rise in hematocrit, blood viscosity or blood
volume since HTN occurred despite prevention of hypoxia-
induced erythrocytosis by repeated phlebotomies. More-
over, the HTN persisted long after the restoration of
normoxia and normal hematocrit and blood volume [1].
The rise in arterial blood pressure began within a few days
after exposure to hypobaric hypoxia and was preceded by a
threefold increase in plasma endothelin concentration [1].
This observation was consistent with the reported increase
in plasma endothelin-1 in human volunteers following an
ascend from a 490 to 4,559 meter altitude leading to acute
pulmonary hypertension [2]. It is of note that hypoxia
results in up-regulation of endothelin and ET-A and ET-B
receptor gene expressions in the lung [3]. Moreover, hy-
poxia-induced pulmonary hypertension can be mitigated by
endothelin-1 receptor blockade [4]. These observations
point to the role of endothelin in the pathogenesis of
hypoxia-induced pulmonary hypertension. In addition, in-
travenous infusion of endothelin-1 has been shown to cause
sustained systemic HTN which can persist long after endo-
thelin-1 administration.
Basal production of nitric oxide (NO) is essential for
maintenance of the vasodilatory tone and normal blood
pressure. Several studies have demonstrated a significant
down-regulation of endothelial NO synthase (eNOS) ex-
pression with hypoxia in cultured endothelial cells [5, 6].
Based on the above observations, we hypothesized that
hypoxia-induced HTN may be mediated by increased en-
dothelin production and/or depressed NO generation. The
present study was, therefore, designed to test this hypothesis.
METHODS
Male Sprague-Dawley rats (Harlan Sprague Dawley Inc.,
Indianapolis, IN, USA) weighing 200 to 225 g were fed
regular rat chow (Purina Rat Chow; Purina Mills Inc.,
Brentwood, MO, USA) and water ad libitum. The rats were
randomly assigned to the following groups:
Group A. Rats assigned to this group were implanted
with osmotic pumps (Alza Inc., Palo Alto, CA, USA) that
were loaded with the endothelin receptor (ET-A/B) antag-
onist, L-754,142 (Merck Inc., Rahway, NJ, USA). The
pump delivered the drug at a rate of 5 mg/kg/day through-
out the 24-day hypoxic period. During this period animals
were placed in a hypobaric chamber in which the air
pressure was kept at 390 mm Hg using a continuous
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vacuum pump and an adjustable inflow valve. The interior
of the chamber was kept at the ambient temperature, and
the normal interior light cycle was accommodated through
a glass window in the chamber wall. The animals were kept
within the chamber for 24 days. The chamber was briefly
opened three times a week for routine animal care, mea-
surement of tail arterial blood pressure and procurement of
blood samples for hematocrit.
Group B. Rats in group B were implanted with unloaded
osmotic pumps and received L-arginine (Sigma Co., St.
Louis, MO, USA) supplementation in their drinking water
(0.5 g/dl). These animals were exposed to hypobaric hyp-
oxia in a manner identical to that described for group A.
Group C. Rats assigned to this group were implanted
with unloaded osmotic pumps and were exposed to hypo-
baric hypoxia in a fashion similar to that of groups A and B
animals.
Group D. Animals assigned to this group were placed in
the chamber at normal atmospheric pressure.
Arterial blood pressure was measured using a tail sphyg-
momanometer (Harvard Apparatus, South Natick, MA,
USA). Blood samples were obtained by orbital sinus punc-
ture. Hematocrit was determined by microhematocrit
method.
In an attempt to determine urinary excretion of NO
metabolites, four-hour urine collections were obtained at
baseline and at various intervals during hypoxia (at 4 hr, 8
hr and on days 1, 2, 3, 7, and 14) and immediately after the
end of the hypoxic period (day 24). On each occasion,
animals were placed in individual metabolic cages within
the hypobaric chamber, and urine was collected over
crushed ice. Urinary concentration of total nitrates and
nitrites (NOx) was measured using the Sievers Nitric Oxide
Analyzer (Sievers Instruments Inc., Boulder, CO, USA) as
previously described [7]. The values obtained were normal-
ized against urinary creatinine excretion.
Endothelin determination
Plasma endothelin was measured by radioimmunoassay
(RIA) using reagents obtained from Nichols Institute Di-
agnostics (San Juan Capistrano, CA, USA). EDTA plasma
samples were extracted with acetone, and the acetone
extract was dried under nitrogen (extraction efficiency was
90%). The dried extract was reconstituted and assayed in
an RIA using 125I-endothelin and rabbit anti-endothelin.
The bound/free separation was achieved using second
antibody separation procedure (donkey anti-rabbit gamma
globulin). To avoid interassay variations, all samples were
assayed in a single session. The intra-assay variation for this
test was less than 8%. Sensitivity of the assay was 1 pg/ml
for a 1 mL sample size. The specificity of the antibody was
as follows: endothelin 1 to 100%, endothelin 2 to 52% and
endothelin 3 to 96%. The assay had minimal crossreactivity
with big endothelin (7%) and no cross reactivity with ANP,
AVP, angiotensin II or ACTH.
Statistical analysis
Repeated measure analysis of variance (ANOVA) and
Duncan’s multiple range test were used in evaluation of the
data that are presented as mean 6 SEM. P values equal to or
less than 0.05 were considered significant.
RESULTS
Effects of hypoxia
Data are shown in Table 1 and Figures 1 and 2. The
placebo-treated hypoxic group showed a steady rise in
hematocrit and arterial blood pressure beginning a few
days following the onset of hypoxia. This was preceded by
a marked rise in plasma endothelin concentration which
peaked 48 hours after exposure to hypoxia. In contrast,
urinary NOx excretion fell markedly early in the course of
hypoxia reaching a nadir within 48 hours. Thereafter,
urinary NOx gradually rose reaching normal values by day 7.
Effect of ET-A/B receptor blockade
Data are shown in Figures 3 and 4. ET-A and ET-B
receptor blockade with L-754,142 led to a more severe and
Fig. 1. Tail systolic blood pressure in placebo-treated rats exposed to
hypobaric hypoxia (f) and the control animals (,) kept at normal
atmospheric pressure for 24 days. N 5 6 in each group; *P , 0.05, **P ,
0.01 versus normal control.
Table 1. Hematocrit and body weight obtained prior to (initial) and
after the conclusion (final) of the study in placebo-treated (Pl-Rx),
endothelin-1 receptor blocker-treated (ERB-Rx), L-arginine-treated
(Arg-Rx) hypoxic groups and normal control groups
Groups
Body weight g Hematocrit %
Initial Final Initial Final
Control 221 6 4.1 312 6 5.7a 43.5 6 0.61 46.1 6 0.62
Pl-Px 224 6 2.8 284 6 3.9a,b 44.8 6 0.54 69.3 6 0.39a,b
ERB-Rx 219 6 3.3 291 6 4.2a,b 43.7 6 0.77 67.2 6 0.48a,b
Arg-Rx 217 6 3.5 288 6 4.8a,b 44.5 6 0.56 69.4 6 0.71a,b
Rx is treated.
a P ,0.05 vs. initial value.
b P ,0.05 vs. corresponding value in the control group.
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longer lasting reduction of urinary NOx excretion when
compared with the untreated hypoxic group. Moreover, the
treatment did not mitigate the hypoxia-induced HTN. In
addition, ET-A/B receptor blockade did not affect the
hypoxia-induced erythrocytosis.
Effect of L-arginine supplementation
Data are illustrated in Figures 3 and 4. Compared to the
untreated controls, L-arginine-treated rats showed a signif-
icant improvement in urinary NOx excretion. In addition,
the rise in arterial blood pressure seen in the placebo-
treated and ET-A/B blocker-treated animals did not occur
in rats receiving L-arginine supplementation. Thus, L-
arginine administration mitigated the fall in urinary NOx
excretion and abrogated the development of HTN in rats
subjected to prolonged hypobaric hypoxia. As with ET-A/B
blocker (L-754,142), L-arginine did not affect hypoxia-
induced erythrocytosis.
DISCUSSION
In a recent study we found that, under the given condi-
tions, prolonged hypobaric hypoxia leads to a hematocrit-
independent, severe sustained systemic HTN that persists
long after restoration of normoxia. This was associated with
a significant rise in plasma endothelin level preceding the
onset of systemic HTN. Although the peak plasma endo-
thelin concentration occurred before the onset of HTN, the
endothelin level did not return to the baseline level until
fourteen days after the onset of hypoxia [1]. This observa-
tion suggested that elevation of endothelin may have
contributed to the associated HTN. If true, continuous
endothelin receptor blockade would be expected to miti-
gate the associated HTN. Contrary to expectation, the
study showed that treatment with endothelin-1 receptor
antagonist did not mitigate the hypoxia-induced systemic
HTN in this model. This is in contrast to the hypoxia-
induced pulmonary hypertension that can be ameliorated
or reversed by endothelin receptor blockade in rats exposed
to acute or chronic hypoxia [4, 8]. The differential effects of
endothelin-1 receptor blockade on hypoxia-induced sys-
temic HTN and pulmonary hypertension may be, in part,
due to the greater endothelin abundance and endothelin
Fig. 2. Plasma concentration of endothelin (A) and urinary excretion of
total nitrates and nitrites (NOx, B) in rats exposed to hypobaric hypoxia
(F) and normoxia (l) for 24 days. N 5 6 in each group. *P , 0.05. **P ,
0.01 versus baseline and control values.
Fig. 3. Systolic arterial blood pressure in placebo-treated (f), ET-A/B
receptor blocker-treated (l) and L-arginine-treated (,) rats exposed to
hypobaric hypoxia for a 24-day period. A minimum of six animals were
included in each group. *P , 0.05. **P , 0.01 versus other groups.
Fig. 4. Urinary excretion of total nitrates and nitrites (NOx) in placebo-
treated (F), L-arginine-treated (,) and ET-A/B receptor blocker-treated
(l) hypoxic groups. A minimum of six animals were included in each
group. *P , 0.05. **P , 0.01 versus placebo-treated hypoxic group.
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sensitivity of the pulmonary vasculature as compared to the
systemic blood vessels [4].
Nitric oxide (NO), otherwise known as endothelium-
derived relaxing factor (EDRF), plays a major role in
regulation of vascular smooth muscle tone and hence
arterial blood pressure in normal conditions [9]. Moreover,
inhibition of NO production by NO synthase blockade
leads to sustained systemic hypertension [10, 11]. It is of
note that hypoxia leads to depressed L-arginine:NO path-
way in the lungs. This is thought to play a role in the genesis
of hypoxia-induced pulmonary hypertension [12, 13]. In
fact, NOS blockade has been shown to worsen and NO
administration (in the inhaled air) to ameliorate hypoxia-
induced pulmonary hypertension [14]. In view of these
considerations, we sought to determine the effect of pro-
longed hypobaric hypoxia and endothelin-1 receptor block-
ade on urinary excretion of NOx as a rough estimate of
renal and systemic NO production. We found a sharp, early
reduction in urinary NOx excretion followed by a gradual
rise towards baseline values during the hypoxic period. The
reduction in NO production in the hypoxic animals pre-
ceded the rise in arterial blood pressure. L-arginine sup-
plementation mitigated the rise in arterial blood pressure
and the fall in urinary NOx excretion in the hypoxic
animals. This observation suggests that depressed NO
production may play an important role in the pathogenesis
of hypoxia-induced hypertension. The reduction in NO
production with hypobaric hypoxia in rats employed here is
consistent with the reported effect of hypoxia in cultured
endothelial cells in vitro [5].
It is of note that the peak plasma endothelin-1 and the
trough urinary NOx excretion preceded the rise in arterial
blood pressure. In fact, the onset of hypertension coincided
with the gradual improvements in plasma endothelin-1 and
urinary NOx excretion. The available data do not allow a
definitive explanation for the temporal discordance be-
tween the onset of systemic hypertension and the peak
changes in endothelin-1 and NO production. However, it is
tempting to speculate that acute pulmonary hypertension
and myocardial depression associated with the rapid fall in
oxygen tension may have masked the potential rise in
systemic blood pressure expected to occur with the fall in
NO and the rise in ET-1 production. It can be further
speculated that amelioration of cardiopulmonary dysfunc-
tion with physiological adaptations may have been respon-
sible for the delayed expression of systemic hypertension
with continued hypoxia.
Interestingly, both plasma endothelin and urinary NOx
values were normal during the chronic sustained phase of
hypertension in this model. This observation suggests that,
while the alterations of endothelin and NO productions
may be involved in the induction of hypertension, they are
not necessary for the maintenance of hypertension in this
model. Accordingly, it appears that a combination of
extended hypobaric hypoxia with the resultant transient
disorders of endothelin and NO production among other
factors is sufficient to induce sustained systemic hyperten-
sion in this model. Our data suggest that this phenomenon
can be interrupted by augmentation of L-arginine:NO
system but not by inhibition of ET-A/B receptors.
It is of interest that the magnitude and duration of
decline in urinary NOx excretion was amplified by ET-A/B
receptor blockade. This phenomenon can be readily ex-
plained by the loss of the stimulatory action of endothelin,
through ET-B receptor, on NO and prostacyclin produc-
tion [15–17]. The reduction in NO and prostacyclin pro-
duction with ET-A/B blockade may account for the lack of
discernible improvement of hypertension in this setting.
This is because the vasodilatory action of ET-1 antagonist
may have been offset by the concurrent reduction in
prostacyclin and NO-mediated vasodilation.
In contrast to the present model of chronic hypobaric
hypoxia, which is marked by systemic hypertension, most
reported models of acute and chronic hypoxia-induced
pulmonary hypertension have normal systemic blood pres-
sures [8, 18]. The reason for the disparity in systemic blood
pressure between these models is not entirely clear. How-
ever, several factors such as duration, severity and type of
hypoxia (that is, normobaric vs. hypobaric) may account for
this disparity. For instance, the short duration of studies of
acute hypoxia precludes detection of systemic hypertension
which as shown here occurs a few days after the onset of
hypoxia. In addition, the severity of hypoxia is generally
greater in the common models of chronic hypoxia-induced
pulmonary hypertension and core pulmonale. The reduc-
tion in cardiac output due to severe pulmonary hyperten-
sion and core pulmonale can clearly offset the effect of
elevated systemic vascular resistance and thereby obscure a
potential systemic hypertension. Moreover, while uncer-
tain, the normobaric or hypobaric nature of hypoxia may be
a determining factor as well. Further studies are required to
address these possibilities.
In conclusion, prolonged hypobaric hypoxia led to severe
systemic hypertension in genetically normotensive
Sprague-Dawley rats confirming our previous observations
[1]. This was associated with a transient rise in plasma
endothelin and a marked reduction in urinary excretion of
NO metabolites. Continuous administration of ET-A/B
receptor antagonist failed to improve the associated hyper-
tension. However, L-arginine supplementation prevented
the rise in blood pressure and mitigated the fall in urinary
NOx excretion in this model. These findings point to the
possible role of depressed renal and systemic NO produc-
tion in the pathogenesis of arterial hypertension in this
model.
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